Relationship between baseline dFLC and change in dFLC during cycle 1 and hematologic response rates after 1, 2, and 4 cycles and at the end of treatment
| Hematologic response rates . | High baseline dFLC* (>124.2 mg/L) . | Low baseline dFLC* (≤124.2 mg/L) . | High dFLC decrease during cycle 1† (>59%) . | Low dFLC decrease during cycle 1† (≤59%) . |
|---|---|---|---|---|
| After cycle 1 | ||||
| Patients evaluable, nঠ| 31 | 35 | 32 | 33 |
| Hematologic response rate, n (%) | 12 (39) | 14 (40) | 22 (69) | 4 (12) |
| CR | 1 (3) | 3 (9) | 3 (9) | 1 (3) |
| PR | 11 (35) | 11 (31) | 19 (59) | 3 (9) |
| After cycle 2 | ||||
| Patients evaluable, nঠ| 26 | 33 | 29 | 30 |
| Hematologic response rate, n (%) | 13 (50) | 17 (52) | 23 (79) | 7 (23) |
| CR | 2 (8) | 6 (18) | 6 (21) | 2 (7) |
| PR | 11 (42) | 11 (33) | 17 (59) | 5 (17) |
| After cycle 4 | ||||
| Patients evaluable, nঠ| 20 | 28 | 23 | 25 |
| Hematologic response rate, n (%) | 14 (70) | 15 (54) | 20 (87) | 9 (36) |
| CR | 1 (5) | 6 (21) | 4 (17) | 3 (12) |
| PR | 13 (65) | 9 (32) | 16 (70) | 6 (24) |
| End of treatment | ||||
| Patients evaluable, nঠ| 28 | 31 | 27 | 31 |
| Hematologic response rate, n (%) | 12 (43) | 18 (58) | 21 (78) | 9 (29) |
| CR | 5 (18) | 10 (32) | 11 (41) | 4 (13) |
| PR | 7 (25) | 8 (26) | 10 (37) | 5 (16) |
| Hematologic response rates . | High baseline dFLC* (>124.2 mg/L) . | Low baseline dFLC* (≤124.2 mg/L) . | High dFLC decrease during cycle 1† (>59%) . | Low dFLC decrease during cycle 1† (≤59%) . |
|---|---|---|---|---|
| After cycle 1 | ||||
| Patients evaluable, nঠ| 31 | 35 | 32 | 33 |
| Hematologic response rate, n (%) | 12 (39) | 14 (40) | 22 (69) | 4 (12) |
| CR | 1 (3) | 3 (9) | 3 (9) | 1 (3) |
| PR | 11 (35) | 11 (31) | 19 (59) | 3 (9) |
| After cycle 2 | ||||
| Patients evaluable, nঠ| 26 | 33 | 29 | 30 |
| Hematologic response rate, n (%) | 13 (50) | 17 (52) | 23 (79) | 7 (23) |
| CR | 2 (8) | 6 (18) | 6 (21) | 2 (7) |
| PR | 11 (42) | 11 (33) | 17 (59) | 5 (17) |
| After cycle 4 | ||||
| Patients evaluable, nঠ| 20 | 28 | 23 | 25 |
| Hematologic response rate, n (%) | 14 (70) | 15 (54) | 20 (87) | 9 (36) |
| CR | 1 (5) | 6 (21) | 4 (17) | 3 (12) |
| PR | 13 (65) | 9 (32) | 16 (70) | 6 (24) |
| End of treatment | ||||
| Patients evaluable, nঠ| 28 | 31 | 27 | 31 |
| Hematologic response rate, n (%) | 12 (43) | 18 (58) | 21 (78) | 9 (29) |
| CR | 5 (18) | 10 (32) | 11 (41) | 4 (13) |
| PR | 7 (25) | 8 (26) | 10 (37) | 5 (16) |
Groups were defined based on a median baseline dFLC of 124.2 mg/L.
Groups were defined based on a median percentage decrease in dFLC from baseline to the last visit of cycle 1 of 59%.
For the high vs low baseline dFLC comparison, evaluable responses available for 66 patients after cycle 1, 59 patients after cycle 2, 48 patients after cycle 4, and 59 patients at the end of treatment.
For the high vs low dFLC decrease comparison, evaluable responses available for 65 patients after cycle 1, 59 patients after cycle 2, 48 patients after cycle 4, and 58 patients at the end of treatment.